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NPHS2 mutation analysis shows genetic heterogeneity of
steroid-resistant nephrotic syndrome and low post-transplant
recurrence.
Background. Mutations of NPHS2 are causative in famil-
ial autosomal-recessive (AR) and sporadic steroid-resistant
nephrotic syndrome (SRNS). This study aimed to determine
the spectrum of NPHS2 mutations and to establish genotype-
phenotype correlations.
Methods. NPHS2 mutation analysis was performed in 338 pa-
tients from 272 families with SRNS: 81 families with AR SRNS,
172 patients with sporadic SRNS, and 19 patients with diffuse
mesangial sclerosis (DMS).
Results. Twenty-six different pathogenic NPHS2 mutations
were detected, including 13 novel mutations. The mutation
detection rate was 43% for familial AR and 10.5% for spo-
radic SRNS, confirming genetic heterogeneity. No pathogenic
NPHS2 mutations were found in DMS patients. Age at onset in
patients with two pathogenic mutations was earlier, especially
in cases with frameshift, truncating, and the R138Q missense
mutations. Patients with only one NPHS2 mutation or variant
had late-onset NS. Triallelic inheritance was observed in one pa-
tient with a homozygous R138Q mutation and a de novo NPHS1
mutation. Among 32 patients with two NPHS2 mutations who
underwent kidney transplantation, only one developed late re-
currence of focal segmental glomerulosclerosis (FSGS). Among
25 patients with sporadic SRNS and post-transplantation recur-
rence, we detected a heterozygous NPHS2 mutation in one case,
and heterozygous variants/polymorphisms in 3 cases.
Conclusion. Patients with two pathogenic NPHS2 mutations
present with early-onset SRNS and very low incidence of post-
transplantation recurrence. Heterozygous NPHS2 variants may
play a role in atypical cases with mild, late-onset course, and
recurrence after transplantation.
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Nephrotic syndrome (NS) is frequently seen as an id-
iopathic primary disease that represents a heterogeneous
group of glomerular disorders occurring mainly in chil-
dren. It is generally divided into steroid-sensitive and
steroid-resistant forms, depending upon the patient’s re-
sponse to steroid therapy. While most patients show a fa-
vorable outcome after steroid treatment, 10% of children
with idiopathic NS do not respond to steroids or to any
other immunosuppressive therapy, and progress to end-
stage renal disease (ESRD). Renal histology typically
shows focal segmental glomerulosclerosis (FSGS). Fur-
thermore, in approximately one third of transplanted pa-
tients, the clinical course is complicated by a recurrence of
proteinuria, histologically characterized by reappearance
of FSGS in the transplanted kidney, which may ultimately
compromise allograft function [1]. Several pathogenic
factors have been postulated in these cases of recurrent
disease after transplantation, among these a proteinuric
circulating permeability factor, so far unidentified, pro-
duced in the setting of T-cell dysfunction [2, 3].
Diffuse mesangial sclerosis (DMS) is a separate his-
tologic entity, clinically presenting with SRNS in early
childhood and rapidly leading to ESRD in the first years
of life. Renal histology shows enhanced production of
mesangial matrix, thickening of the glomerular basement
membrane (GBM), and podocyte hypertrophy.
Over the last decade, mutations in genes encoding
podocyte proteins have been identified in several forms of
hereditary NS. Mutations in the Wilm’s tumor suppres-
sor gene WT1 were discovered in patients with Denys-
Drash, Frasier syndrome, and DMS [4–7]. NPHS1, which
encodes nephrin, has been identified as the causative gene
in congenital NS of the Finnish type (CNF) [8]. Mutations
in ACTN4 encoding a-actinin-4 were discovered in sev-
eral families with autosomal-dominant FSGS, a form of
hereditary NS with late onset and progression to ESRD
[9]. Very recently, a heterozygous splice-site mutation
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in CD2AP, encoding CD2-associated protein, a compo-
nent of the glomerular filtration complex, was described
in two unrelated patients with primary FSGS, pointing
to additional genes which might be involved in human
susceptibility to glomerular disease [10]. By positional
cloning, a novel podocyte-specific protein, podocin, en-
coded by NPHS2 on chromosome 1q25-31 and associated
with autosomal-recessive forms of SRNS, was described
by Boute et al [11]. Podocin is a 383-amino acid mem-
brane protein that shares sequence homology with pro-
teins of the band-7 stomatin family. It has a predicted
hairpin-like structure and is expressed exclusively at the
slit diaphragm, with both protein termini on the cytosolic
side [12]. Podocin has been shown to accumulate in an
oligomeric form in the slit diaphragm, where it interacts
with CD2AP and nephrin [13]. It has been postulated that
podocin may serve a scaffolding function in lipid rafts, and
it has also been shown to direct the targeting of nephrin to
lipid rafts, where it augments nephrin signaling [14–16].
NPHS2 mutations were first detected in familial
autosomal-recessive SRNS, which manifests early in
childhood and presents histologically with FSGS [11].
Thereafter, NPHS2 mutations were also identified in spo-
radic cases of SRNS [17–19], late onset FSGS [20], and,
surprisingly, in a few patients with recurrence of pro-
teinuria after renal transplantation [21]. Since the dis-
covery of podocin, we have performed mutational anal-
ysis and clinical follow-up of a large cohort of patients
with either familial or sporadic SRNS originating mainly
from France and North African countries. We present
our results, correlating the age of onset and likelihood
of post-transplantation recurrence in these patients with
the nature of the underlying NPHS2 mutation/variant,
and compare our results with other published series
[17–24].
METHODS
Patients
A total of 338 patients belonging to 272 families were
included in the present study. They originated from a
large number of countries worldwide, most of them,
however, from Europe (mainly France) and from North
Africa. Of these, 319 presented with SRNS, defined as
lack of response to four weeks of treatment with pred-
nisone followed by three bolus injections of methyl-
prednisolone. Among them, 147 patients belonging to
81 families (44 being consanguineous) were classified as
autosomal-recessive (AR) SRNS, defined as SRNS in
families with either two or more affected children, or one
(or more) affected individual in consanguineous fami-
lies. This group included 16 families that were previously
described in our initial study [11]. One hundred seventy-
two patients presented with sporadic SRNS. Other distant
family members were affected with proteinuria or NS in
7 cases. As the patterns of inheritance in these families
were not suggestive of autosomal-recessive disease, the
index cases were included in the group of sporadic SRNS.
In addition, 19 patients (of 19 families) with DMS were
also included in the present study.
Mean age at manifestation of NS was recorded in 286
patients and was 57.6 ± 6.8 months in AR SRNS (N =
107), whereas it was higher in sporadic cases (102.9 ±
8.9 months; N = 169), especially in the cases with recur-
rence after transplantation (134.3 ± 27.3 months; N =
24). Manifestation was early in the patients affected by
DMS (22.1 ± 5.8 months; N = 10). In total, as most of the
patients were recruited through pediatric nephrology de-
partments, only 37 developed NS after 15 years (4 patients
with AR SRNS and 33 patients with sporadic SRNS, 7 of
them with post-transplantation recurrence).
For 261 patients, the results of at least one kidney
biopsy were provided to us (106 patients with AR SRNS
and 155 sporadic cases). These evaluations showed that 65
patients had predominantly minimal changes (23 patients
with AR SRNS, 42 sporadic cases) and 172 patients had
FSGS (68 patients with AR SRNS, 104 sporadic cases).
In a few cases, mesangial proliferation was observed
(15 patients with AR SRNS, 9 sporadic cases) without
glomerulosclerosis.
Information on renal transplantation was available for
115 patients with AR SRNS and 170 patients with spo-
radic SRNS. Transplantation was performed in 44 of the
115 patients with AR SRNS, and no early recurrence was
observed in these cases. However, one patient developed
proteinuria and FSGS 2 years after receiving an allo-
graft. Among the group of sporadic SRNS, 74 underwent
kidney transplantation and 25 of them had a recurrence
of proteinuria. In 16 of these, early recurrence was di-
agnosed immediately after transplantation. Six patients
showed a recurrence 14 days to 18 months after trans-
plantation. No post-transplant data were available for
3 patients.
Genotyping and haplotype analysis
Peripheral blood samples were obtained after in-
formed consent of the patients or their parents. Genomic
DNA was extracted according to standard labora-
tory protocols. Five polymorphic microsatellite markers
(D1S3758, D1S3760, D1S215, D1S3759, D1S2883) span-
ning 1.1 cm and flanking the NPHS2 locus were tested.
Genotyping was performed after PCR amplification and
electrophoresis as previously described in Fuchshuber
et al [25]. Cyrillic 2.1 (Cherwell Scientific, Oxford, UK)
was used to construct pedigrees and to perform haplotype
analysis.
Mutation screening
Mutation analysis for NPHS2 was carried out by single-
strand conformation polymorphism (SSCP) analysis for
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exons 2–7, as described previously in Boute et al [11], and
by direct sequence analysis for exons 1 and 8. Exons of
the NPHS1 gene were amplified by PCR using flanking
intronic primers [26] and subsequently sequenced. Direct
sequencing was carried out using the Big Dye-terminator
method (Applied Biosystems, Foster City, CA, USA). Se-
quences were evaluated with the Sequencher software
(Gene Codes, Ann Arbor, MI, USA). Segregation anal-
ysis of mutations in families was performed by direct se-
quencing, SSCP analysis, or specific restriction enzyme
digestion.
Genotyping by single-base extension (SBE)
and electrophoresis
In order to discriminate mutations from polymor-
phisms, all detected missense mutations were screened
in 320 control chromosomes by single-base extension us-
ing SNaPshot Multiplex kit (Applied Biosystems). We
expanded the control cohort to 75 individuals (150 chro-
mosomes) of African descent for the screening of the
A242V variant. Exons were amplified using flanking in-
tronic primers. The PCR products from 4 to 6 exons
were then mixed with 1.5 lL of ExoSAP-IT (Amersham
Bioscience) and incubated for 1 hour at 37◦C to re-
move primers and dNTP, followed by 15 minutes at 80◦C
for enzyme inactivation. Primer extension reactions [27]
were performed according to manufacturer’s protocol.
To clean up the single-base extension reaction, one unit
of shrimp alkaline phosphatase (Amersham Bioscience)
was added to the reaction and then incubated for 1 hour
at 37◦C, followed by 15 minutes at 80◦C for enzyme in-
activation. The extension products were denatured for
5 minutes at 95◦C, and electrophoresis was performed us-
ing ABI Prism 373 A DNA Sequencer (Applied Biosys-
tems). The results were analyzed using Genescan Analy-
sis and Genotyper (Applied Biosystems).
Statistical analyses
Values reported are the mean ± standard error of the
mean (SEM). Statistical comparisons were performed us-
ing one-way analysis of variance (ANOVA). P values of
< 0.05 were considered significant.
RESULTS
Linkage analysis
In 62 families suggestive of AR SRNS, linkage analyses
were performed with markers flanking the NPHS2 gene
locus on chromosome 1q25-31. Results were compatible
with linkage to this locus in 36 families, and pathogenic
NPHS2 mutations were identified in 25 of them. In the
remaining 11 families (all consanguineous, 10 with only
one affected child), linkage was compatible as evidenced
by homozygosity for the polymorphic makers flanking
NPHS2, but no pathogenic NPHS2 mutations were iden-
tified. Linkage to the NPHS2 locus was excluded in 26
families, and we performed NPHS2 mutation screening in
17 of these families in parallel. No NPHS2 mutations were
detected, as was expected, and further mutation analysis
in the 9 additional families was not performed.
Homozygous, compound heterozygous, and single
heterozygous pathogenic NPHS2 mutations
NPHS2 mutation screening was thus performed in 322
patients from 263 families. Pathogenic mutations were
defined as variants that (1) were not found in 320 healthy
control chromosomes, (2) segregated with the disease in
families, and (3) were predicted to severely alter pro-
tein sequence and/or expression levels. Homozygous or
compound heterozygous mutations were identified in 73
patients (42 families), of whom 62 patients presented clin-
ically with AR SRNS (31 families), and 11 with sporadic
SRNS. We did not identify pathogenic NPHS2 mutations
in any patient with isolated DMS (Table 1).
In addition, only one pathogenic NPHS2 mutation was
identified in 2 patients from one family with AR SRNS
and in 6 patients with sporadic SRNS. The entire cod-
ing region and all exon-intron boundaries of NPHS2
were sequenced in order to identify the second muta-
tion, but yielded no additional mutation. Although some
mutations may have been missed, such as heterozygous
deletions, intronic mutations, or mutations in regulatory
regions, it is unlikely that they could account for all the
unidentified mutations. In addition to these 8 patients,
7 patients from 4 families (3 AR SRNS and 1 sporadic
case) presented with compound heterozygosity of one
pathogenic NPHS2 mutation and the R229Q polymor-
phism on the other allele.
The detection rate of NPHS2 mutations in the homozy-
gous or compound heterozygous states for AR SRNS was
38% (31 out of 81 families studied by mutation screening
and/or linkage analysis). On the contrary, mutation detec-
tion rate for sporadic SRNS was five times lower at 6.4%
(11 affected patients of 172 patients studied). If patients
with heterozygous pathogenic NPHS2 mutation with or
without R229Q in compound heterozygosity were also
included, the mutation detection rates rose to 43% for
AR SRNS and to 10.5% for sporadic cases, respectively.
In total, 26 different NPHS2 mutations were detected
in the present study; among these, 13 were novel mu-
tations (Table 2). These newly identified mutations in-
clude missense, nonsense, frameshift and splice-site mu-
tations, and one in-frame deletion of 9 nucleotides, but
no large or complete gene deletions. Some mutations
were found in several unrelated families. In particular,
the R138Q mutation (in exon 3) was observed in 32% of
all affected alleles. A large majority of mutations were lo-
cated in exons 4, 5, and 7, encoding the C-terminal part of
podocin. NPHS2 missense mutations cluster in the early
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Table 1. Overview of genotypic and phenotypic data
AR SRNSa Sporadic SRNSa DMSa
No. of patients (families) 147 (81) 172 (172) 19 (19)
Two NPHS2 pathogenic mutations 62 (31) 11 (11) 0 (0)
One NPHS2 pathogenic mutation 2 (1) 6 (6) 0 (0)
One NPHS2 mutation + R229Q 6 (3) 1 (1) 0 (0)
Mutation detection rate (in total) 43% 10.5% 0%
Homozygous R229Q polymorphism 5 (3) 2 (2) 0 (0)
Heterozygous R229Q polymorphism 0 (0) 11 (11) 2 (2)
Variants in heterozygous state 3 (2) 4 (4) 1 (1)
A242V polymorphism 2 (2) 4 (4) 1 (1)
Age at onset (all) 57.6 ± 6.8 months 102.9 ± 8.9 months 22.1 ± 5.8 months
N = 107 N = 169 N = 10
Age at onset (with two pathogenic NPHS2 mutations) 41.2 ± 5.9 months
N = 63
Age at onset (without two pathogenic NPHS2 mutations) 69.9 ± 11.5 months 108.3 ± 9.4 months
N = 55; P = 0.019b N = 158; P < 0.001b
aNumbers in parentheses refer to affected families.
bP value: age at onset is compared with patients bearing two pathogenic mutations.
Table 2. Summary of mutations, variants, and polymorphisms
Nucleotide Effect on Status (number of
Exon change protein unrelated patients) Reference(s)
Pathogenic mutations
1 85 G>A A29T het (1) Present study
1 104 105insG G35fsX69 c het (1) [11]
1 274 G>T G92C c het (1) [11]
2 275-2 A>C Splice c het (1) Present study
2 353 C>T P118L hom (1), c het (1) Present study
3 412 C>T R138X hom (1) [11, 18, 23]
3 413 G>A R138Q hom (12), c het (7), het (1) [11, 17, 18, 20, 22]
3 419delG G140fsX180 hom (1), c het (1) [11, 17, 18]
4 467delT L156fsX180 hom (1) Present study
4 467 468insT L156fsX166 hom (1), c het (1) [17, 18, 22]
4 479 A>G D160G hom (1) [11]
4 502 C>A R168S c het (1) Present study
4 502 C>T R168C het (1) Present study
4 503 G>A R168H hom (1), c het (1), het (1) Present study
5 538 G>A V180M hom (3), c het (2) [11, 17, 18]
5 555delT F185fsX186 c het (1) [19]
5 622 G>A A208T het (2) Present study
5 705 713del9 L236 R238del hom (1) Present study
5 714 G>T R238S hom (1), c het (1) Present study
6 779 T>A V260E hom (4) Present study
7 851 C>T A284V hom (1), heta (2) [17, 20]
7 855 856delAA Q285fsX302 hom (1), c het (4) [11, 17, 20]
7 862 G>A A288T heta (1) [20]
7 871 C>T R291W heta (1) [11, 17, 20]
8 964 C>T R322X c het (1) Present study
8 976 977insA T326fsX345 het (1) Present study
Variants of unknown significance
1 59 C>T P20L homb (1), het (1) [11, 19]
1 182 C>T A61V hetc (2) Present study
4 514 C>G L172V het (1) Present study
5 709 G>C E237Q het (2) Present study
Nonsilent polymorphisms in the coding sequence
5 686 G>A R229Q hom (5), c het (4), het (13) [17, 20]
5 725 C>T A242V het (7) Present study
Abbreviations are: hom, homozygous mutation; het, single heterozygous mutation; c het, compound heterozygous mutation.
aHeterozygous mutation with the R229Q polymorphism on the second allele; balso with the R168H mutation on the same allele; cone patient with SMD, the other
also bearing the A242V polymorphism.
C-terminal cytoplasmic domain of the podocin protein,
the region conserved among members of the stomatin
protein family (see Fig. 1). Only one mutation (P118L)
was detected in the membrane domain, and 4 (A29T,
G35fsX59; G92C; 275–2 A>C) in the N-terminal part
of podocin. No missense mutations occurred in predicted
N- or O-glycosylation, phosphorylation, or myristolation
sites.
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Fig. 1. Podocin structure and distribution of mutations. Predicted two-dimensional protein structure of podocin with both termini on the cytosolic
side. The region of homology with stomatin is depicted in black. Variants of unknown significance and polymorphisms are shown in italics, nonsense
mutations are underlined, and small insertions/deletions are depicted by arrowheads. One splice-site mutation (275–2 A>C) was identified affecting
the acceptor splice-site of intron 1.
Sequence variations with unknown phenotypic
effects and polymorphisms in NPHS2
Several amino acid substitutions (P20L, A61V, L172V,
E237Q, and A242V) were identified that either do not
markedly alter the predicted protein structure (i.e., con-
servative amino acid change), and/or affect residues that
are not highly conserved among members of the stom-
atin family. These amino acid substitutions were detected
in the heterozygous state in AR and sporadic cases of
SRNS, as well as in two DMS patients. Subsequently, the
frequencies of these sequence changes were screened by
SNaPshot analysis in a control cohort of 320 chromo-
somes. Screening results revealed that none of the healthy
controls showed a P20L, A61V, or L172V sequence vari-
ant, indicating that these substitutions are probably not
polymorphisms. However, in support of a minor role of
these variants, a heterozygous L172V variant was identi-
fied in an AR SRNS family without linkage to the NPHS2
gene locus. A homozygous P20L variant was sequenced
along with a homozygous pathogenic R168H mutation
in a consanguineous family with two affected children.
Finally, the A61V variant was observed in a case of spo-
radic SRNS, as well as in a DMS patient from a consan-
guineous family.
On the contrary, two amino acid substitutions, E237Q
and A242V, were also found in healthy control patients.
The E237Q substitution was identified in 2 sporadic cases
and in 1 control individual (0.3%). This overall fre-
quency in the healthy population is less than 1%, thereby
not fulfilling the definition of an allelic polymorphism.
Heterozygous A242V substitutions were sequenced in 7
patients: 2 with AR SRNS, 4 with sporadic SRNS, and 1
with DMS. It was also detected in 2 out of 320 control
chromosomes (0.6%). Because most patients and both
controls were of African origin, we expanded the control
cohort to 75 individuals (150 chromosomes) of African
descent and detected 6 individuals heterozygous for the
A242V variant, demonstrating that it represents a poly-
morphism in the African population with an allele fre-
quency of 4%.
In addition, the R229Q polymorphism was identified
in 12 out of 320 healthy control chromosomes, defining a
frequency of 3.75%, but never in the homozygous state
in any control individual. This variant has recently been
described by Tsukagushi et al [20] as a non-neutral poly-
morphism. In the present study, a R229Q substitution was
detected in 3 families with AR SRNS and in one patient
with sporadic SRNS, in addition to a pathogenic mutation
on the other allele. Furthermore, homozygous R229Q
mutations were identified in 3 AR SRNS (2 of them be-
ing consanguineous) and in 2 sporadic cases. No addi-
tional NPHS2 mutations were detected in these patients.
In 13 patients (11 with sporadic SNRS and 2 with DMS),
we identified a heterozygous R229Q polymorphism with-
out any other sequence variation in NPHS2. In total, the
screening of 263 unrelated nephrotic patients (526 alleles)
revealed 17 with heterozygous R229Q exchange (3.23%)
and 5 with homozygous R229Q exchange (1.90%), result-
ing in an overall allele frequency in the nephrotic cohort
of 5.13% (P = 0.35 when compared with the frequency of
3.75% in healthy control individuals). In contrast to what
was observed with pathogenic mutations, these variants
and polymorphisms were equally distributed either in the
N-terminus (P20L and A61V) or the C-terminus part of
the protein (L172V, R229Q, E237Q, A242V).
Age at onset
Analysis of the age at discovery of NS was performed
among patients with and without pathogenic NPHS2
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mutations for all cases in whom such data was available.
Patients with pathogenic mutations in homozygous or
compound heterozygous states manifested earlier (41.2 ±
5.9 months, N = 63) than patients without two pathogenic
mutations in NPHS2 for AR SRNS patients (69.9 ±
11.5 months, N = 55; P = 0.019) and for sporadic cases
(108.3 ± 9.4 months, N = 158; P < 0.001). Similar results
were found when only patients developing NS before
15 years of age were analyzed (41.5 ± 6.1 months, N = 60
vs. 57.9 ± 7.5 months, N = 53; P = 0.053 for AR SRNS
and vs. 56.4 ± 4.1 months, N = 127; P = 0.002 for sporadic
cases). With respect to a possible genotype-phenotype
correlation, some trends were apparent. Patients with
frameshift or nonsense mutations in the homozygous or
compound heterozygous state had an early mean age of
onset (21.9 ± 5.6 months, N = 13), as was the case with
homozygous R138Q patients (11.8 ± 3.2 months, N = 15).
Interestingly, in 3 patients with homozygous R138Q mu-
tations, the first clinical symptoms appeared at birth, re-
sembling an intermediate phenotype between congenital
and infantile NS. We therefore performed NPHS1 muta-
tion analysis and found a third (heterozygous) mutation
in NPHS1 (275–2 A>C acceptor splice-site mutation) in
1 patient. NPHS1 and NPHS2 analysis in the parents of
this patient revealed a heterozygous R138Q-NPHS2 mu-
tation in both parents, but no mutations were identified
in NPHS1, thereby reflecting a de novo mutation in the
patient.
On the contrary, some missense mutations were associ-
ated with milder clinical course. In particular, the V180M
and the R238S variants were identified in patients with
a later onset of SRNS with a median age of 128.7 ±
12.4 months (N = 7). Also, patients with a heterozygous
R229Q exchange in addition to one pathogenic NPHS2
mutation and patients with just one heterozygous muta-
tion or variant of unknown significance have a later on-
set in our study cohort (88.1 ± 12.6 months, N = 7 and
147.4 ± 50.0 months, N = 11, respectively).
NPHS2 mutations and recurrence of proteinuria
after renal transplantation
In total, 32 patients with NPHS2 pathogenic muta-
tions, either in the homozygous or compound heterozy-
gous state, underwent kidney transplantation. Among
them, only one developed recurrence of proteinuria two
years after its third renal transplantation. This patient
belongs to a consanguineous family with 3 affected chil-
dren, and harbors the R138X nonsense mutation. The
first and second renal allografts were lost immediately
due to acute rejection and acute allograft failure, respec-
tively. Two years after the third allograft (with mother as
donor), nephrotic-range proteinuria was detected with
renal biopsy disclosing both FSGS and tacrolimus toxi-
city, but no evidence of rejection. Having shown previ-
ously that no NPHS2 mRNA could be detected in this
patient’s native kidney [11], we assayed for serum an-
tipodocin antibodies by indirect immunofluorescence on
normal human kidney. However, no antipodocin antibod-
ies were found. In addition, NPHS2 mutation analysis in
25 patients with sporadic SRNS and a recurrence of pro-
teinuria after renal transplantation revealed heterozy-
gous variants in 3 patients, namely T326fsX345, P20L,
and E237Q (vs. 2 heterozygous variants/mutations out
of 49 transplanted patients with sporadic SRNS and no
recurrence of proteinuria after transplantation). The pa-
tient with a heterozygous pathogenic T326fsX345 muta-
tion developed proteinuria 18 days after transplantation,
and had FSGS on biopsy one year later, ultimately los-
ing the allograft after four years. The second patient with
heterozygous P20L variant had a rapid reappearance of
proteinuria and allograft rejection immediately after re-
ceiving the first transplant. Because renal biopsy showed
thrombotic microangiopathy, the contribution of the pro-
teinuric state to allograft loss is likely minimal. How-
ever, three months after receiving a second transplant,
the patient once again developed massive proteinuria,
requiring plasmapheresis in addition to immunosuppres-
sive therapy, including tacrolimus. The patient bearing the
E237Q substitution presented with proteinuria and NS
18 months after renal transplantation, which resolved af-
ter treatment with iv cyclosporine A and plasmapheresis.
In addition, a fourth patient with heterozygous R229Q
exchange developed FSGS and proteinuria 22 months
after renal transplantation. In all patients, subsequent di-
rect sequencing of the entire NPHS2 coding region and
adjacent exon-intron boundaries revealed no second mu-
tation/variant.
DISCUSSION
Our study involving 338 individuals presenting with
SRNS represents the largest cohort of patients published
to date, and includes both familial autosomal-recessive
and sporadic cases. We established a significant contribu-
tion of mutations of the NPHS2 gene encoding podocin
because more than half (36/62) of families with AR SRNS
were compatible with linkage. Pathogenic variants were
discovered in 25 of these families, but not in those in
whom linkage was not established. We would, therefore,
advocate the use of haplotype analysis, using NPHS2
flanking polymorphic markers as an initial diagnostic
tool in these families, followed by more rigorous muta-
tion detection when linkage is compatible. The detection
of ∼40% of mutations in the families with autosomal-
recessive inheritance demonstrates the preponderance
of NPHS2 mutations in familial SRNS and confirms ge-
netic heterogeneity in SRNS. This is a finding highly
reminiscent of autosomal-dominant FSGS [28], and
emphasizes the need for identifying additional genes
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involved in familial forms of SRNS. We have extended
previously published analyses of sporadic cases of SRNS
[17, 19] by analyzing 172 patients. These patients have a
significantly later onset of NS than familial cases. We re-
port the identification of pathogenic mutations in either
the homozygous or compound heterozygous or heterozy-
gous state in 10.5% of cases, in agreement with results
reported in the two groups of pediatric patients [17, 19].
The lower mutation detection rate among sporadic cases
of SRNS than familial cases, and the delayed onset in
those in whom mutations where not found, point to com-
plex inheritance patterns (as evidenced by the presence
of NS in distant relatives in seven cases), and to potential
gene-environment interactions in patients with sporadic
NS.
Furthermore, we have shown that NPHS2 mutations
are not causative in patients with WT1-negative cases
of DMS. We included 19 patients with DMS in this co-
hort based on previous observations that patients with
WT1 mutations can present either with FSGS (Frasier
syndrome) or DMS (Denys-Drash syndrome) [6, 7]. Fur-
thermore, Nphs2-deficient mice develop renal failure sec-
ondary to DMS [29]. Our data, however, do not sup-
port a pathogenic role for podocin in this subset of
patients.
We have identified 32 NPHS2 variants, 26 of which
are clearly pathogenic mutations on the basis of delete-
rious effects on gene expression or predicted structural
alteration of the protein. Several of these mutations were
identified in unrelated families. The majority of these are
missense mutations (15/26), but also include frameshift-
ing (7/26), in-frame deletion (1/26), nonsense (2/26), and
splice-site (1/26) mutations. Of these, we here report 13
novel mutations in addition to four nucleotide substi-
tutions of unclear significance based on a conservative
change in the amino acid and the lack of residue con-
servation among stomatin family members. We have also
identified the previously reported A242V variant [19] as
a polymorphism enriched among patients of African ori-
gin. In addition, we sequenced the R229Q polymorphism
with an overall frequency of 5.12% among our cohort of
nephrotic patients.
The mutations are distributed throughout the entire
gene, most affecting the C-terminal cytosolic domain. In-
terestingly, 21/26 variants affect the region of homology
with the stomatin protein family [11]. The accumulation
of mutations in this region correlates with the important
functional roles ascribed to this domain, namely homo-
oligomerization and interaction with other slit diaphragm
proteins like nephrin, CD2AP, and the NEPH family [14,
15, 30]. Interestingly, genome database analyses point
to a novel predicted gene (FLJ32940) expressed in hu-
man testis that partly overlaps with exon 6 of the NPHS2
gene, but is oriented in the opposite direction. Fifteen
nucleotides are shared by both genes, but no NPHS2 mu-
tation/variant identified so far affects any of the shared
nucleotides. Were such mutations to occur, as would be
the case with complete NPHS2 deletions, patients might
present with a different phenotype.
The nature of the mutation correlates to some extent
with the age of onset of nephrotic syndrome. Patients with
frameshifting and protein-truncating mutations present
earlier with NS. Among missense variants, severity of the
disease appears to be determined by the impact of the
amino acid substitution on specific functional domains
and on the intracellular trafficking of podocin. Our re-
cent functional studies of the intracellular trafficking of
several podocin mutants demonstrated that certain mis-
sense variants manage to reach the plasma membrane
(V180M and R238S), while others, including R138Q, are
retained in the endoplasmic reticulum (ER) [31]. Huber
et al have similarly shown that the R138Q mutation, while
retaining the ability to homo-oligomerize, is retained in
the ER and fails to recruit nephrin to lipid rafts [16]. The
R138Q mutation, which accounts for 32% of mutant alle-
les in our cohort, predicts mean onset of proteinuria be-
fore the first year of life when present in the homozygous
state. In contrast, patients with the V180M and R238S
mutations have a mean onset of NS much later than pa-
tients with the homozygous R138Q mutations (128 vs.
12 months). It will be interesting to see whether pharma-
cologic approaches that ameliorate the mistrafficking of
the missense podocin variants will allow them to func-
tion properly, as has recently been shown for the F508
CFTR protein [32].
With the enlargement of our cohort, we excluded the
A242V substitution as a true mutation, as previously
reported [19]. We sequenced this variant mostly in the
African population, with an allele frequency of 4%. Ad-
ditional studies will be required to determine whether its
presence imparts an increased susceptibility to protein-
uric renal disease. Likewise, we found the E237Q variant
in two patients and in one control in our large cohort,
therein, highlighting the difficulty of discriminating true
mutations from rare polymorphisms. An equally difficult
task is to ascribe pathogenicity to three missense variants
seen in the heterozygous state, including the P20L substi-
tution, which we identified in two cases (as the sole vari-
ant in one and in conjunction with a homozygous R168H
mutation in another). This variant affects a nonconserved
residue and in our functional analysis reaches the plasma
membrane, while the R168H protein does not [31].
The identification of two pathogenic NPHS2 alleles
in SRNS patients predicts a more severe outcome char-
acterized by earlier onset of disease. This underscores
the crucial role of podocin in the maintenance of the fil-
tration barrier. Among cases where only a single muta-
tion/variant is detected, NS tends to occur later in life.
Caridi et al reported heterozygous variants in patients
with frequently relapsing NS [19], while we found one
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such variant (A61V) in a patient with DMS. One possibil-
ity is that the existence of one hypomorphic podocin allele
predisposes individuals to glomerular dysfunction in the
presence of additional renal insults, as has been recently
suggested by Kim et al regarding CD2AP haploinsuffi-
ciency [10]. We have observed the spontaneous develop-
ment of proteinuria in some aged Nphs2 heterozygous
knock-out mice (C. Antignac, unpublished data). Alter-
natively, these podocin variants may act as modifiers in
the setting of lesions in yet undefined genetic loci. Our
own studies of Nphs2 null mice have revealed a critical
role for genetic modifiers evidenced by disparate rates
of progression of renal failure and survival based on the
underlying mouse strain [29].
Less severe phenotypes have also been noted in fa-
milial cases of FSGS involving a pathogenic mutation on
one allele and the common polymorphism R229Q on the
other allele [20]. Likewise, we detected seven patients be-
longing to four families with similar genotypes and a later
age of onset of nephrotic syndrome. In addition, we found
homozygous R229Q variant in five patients belonging to
three unrelated families and in two sporadic cases.
Interestingly, despite a polymorphism frequency of
0.031, the homozygous R229Q variant has not been iden-
tified so far in control subjects. Although it has been
shown in vitro to encode an altered protein with de-
creased binding affinity to nephrin [20], it remains dif-
ficult to imagine that the R229Q substitution alone, even
in the homozygous state, might be responsible for a se-
vere disease. It is likely that additional sequence muta-
tions in NPHS2 regulatory regions or introns, or variants
in other genes, might explain the phenotype in these pa-
tients. It is, however, noteworthy that we found a higher
frequency, though not significant, of the R229Q variant
among nephrotic patients (5.13% vs. 3.75% in control pa-
tients), confirming previous findings of Tsukagushi et al
[20]. Studies involving greater numbers of patients will
be needed to determine the significance of this finding.
The severity of SRNS might also be modulated by the
presence of additional mutations in genes encoding pro-
teins interacting with podocin. NPHS2 mutations asso-
ciated with NPHS1 variants have already been reported
[19, 22], and we here describe a patient with very early
onset SRNS in whom a heterozygous de novo splice
mutation in NPHS1 and a homozygous NPHS2 R138Q
mutation were detected. This is reminiscent of the tri-
allelic inheritance found in some cases of Bardet-Biedl
syndrome (BBS) [33, 34].
Contrary to previously published data by Bertelli et al
[21], and as would be expected with the resulting struc-
tural alteration of the glomerular filter resulting from
the podocin gene defect, we have found that recurrent
disease after renal transplantation is very unlikely in pa-
tients with two NPHS2 mutations. Out of 32 transplanted
patients with two pathogenic NPHS2 mutations, we ob-
served only one patient, bearing the R138X mutation in
the homozygous state, with recurrent FSGS and a delayed
onset. This rate (1/32) is far below the current rate of re-
currence of 25% in FSGS [1]. Actually, Bertelli et al [21]
detected only two cases with recurrence of proteinuria
after transplantation in patients with NPHS2-R138Q ho-
mozygous mutations, and in both cases, the patients had a
mild episode with a favorable outcome. The mechanisms
underlying these findings are not well defined. Pattraka
et al recently described the presence of antiglomerular
and antinephrin antibodies in the sera of transplanted
patients with CNF who suffered from recurrent NS [35].
Although the development of antibodies directed against
podocin is an attractive explanation for the recurrence of
FSGS in our familial case of SRNS, our data and Bertelli’s
findings [21] do not support this. However, in agreement
with the findings of Bertelli et al, we also found that 3
out of 5 sporadic SRNS patients bearing heterozygous
mutations who were transplanted developed recurrence
[21]. In these patients, the theory of antipodocin antibod-
ies seems rather unlikely because podocin expression will
not be completely abolished. The development of SRNS
when it recurs early after transplantation is commonly
regarded as arising from one or more suggested circulat-
ing permeability factor(s) that alter renal permeability,
leading to proteinuria [2, 3]. As long as these circulating
plasma factors remain unidentified, no clear conclusions
can be drawn from genetic and clinical studies. Neverthe-
less, it can be suggested that NPHS2 mutations/variants
may play a role in modulating the progression of renal
disease before transplantation.
CONCLUSION
The present study shows that the phenotypic spectrum
of patients affected by two clearly pathogenic NPHS2
mutations is restricted to severe early-onset SRNS and
lack of recurrence of proteinuria after renal transplan-
tation. This emphasizes the importance of NPHS2 mu-
tation screening in children with early-onset SRNS to
provide accurate genetic counseling and clinical prog-
nostication. However, heterozygous NPHS2 mutations,
sequence variants, and polymorphisms may play a role in
atypical cases of SRNS with a later onset, mild clinical
course, and recurring disease after renal transplantation.
It can be expected that further genetic studies on families
with NPHS2-negative SRNS will lead to the identification
of new causative genes for SRNS.
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